Using CS generated from isogenic euploid and trisomic cell lines, we demonstrated that administration of MSC-EVs in trisomic CS preserved the size of the spheroids, promoted neurogenesis, diminished cell death, and reduced the depositions Aβ and p-tau, suggesting a novel therapeutic approach to mitigate cellular phenotypes in DS. Here, MAPT is linked to Dravet syndrome.